MS Speaks

Looking at the "optimal profile" for people who might benefit from AHSCT (autologous hematopoietic stem cell transplantation), I'd say that the use of it will be very selective.

RRMS or progressive MS for a short timeRelapses in the previous year, indicating recent clinical inflammatory activityRecent inflammatory activity, as identified by magnetic resonance imagingAge less than 45 yearsDuration of disease of 10 years or lessDisability designated as low to moderateFailure of no more than 2 prior disease-modifying therapiesNo clinically significant comorbiditiesCognitive ability to agree to and adhere to recommended care, especially in immunocompromised phases.

"Emerging evidence on the selective use of AHSCT in MS"--from MedPage Today, October 29, 2018:


https://www.medpagetoday.com/resource-centers/progress-multiple-sclerosis-detection-management/emerging-evidence-selective-use-ahsct-ms/2268?xid=nl_mpt_DHE_2018-10-29&eun=g345846d0r&pos=111111111&utm_source=Sailthru&utm_medium=email&utm_campaign=Daily%20Headlines%202018-10-29&utm_term=Daily%20Headlines%20-%20Active%20User%20-%20180%20days